Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could pregnancy checkups also screen for cancer genes?

NCT ID NCT07052266

Knowledge-focused Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study explores whether offering genetic testing for inherited cancer risk (like BRCA1/2) during routine pregnancy or fertility care is practical and acceptable to patients. Researchers will enroll 550 people receiving prenatal or preconception care at Weill Cornell Medicine. The goal is to see how many complete both standard prenatal genetic screening and the optional cancer risk screening, and to understand if this approach could help catch cancer risks earlier, especially in underserved groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MyRisk Hereditary Cancer Test (genetic screening)
What this could lead to
If successful, this could show that offering cancer genetic testing during pregnancy or fertility care is practical and welcomed, potentially leading to earlier cancer detection and prevention in a broader population.
What could go wrong
This is an early feasibility study, not a treatment trial. It measures interest and completion rates, not health outcomes. Results may not apply to all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 550 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years - 55 years * Pregnant patients receiving obstetrical-related care or receiving preconception/fertility care at a WCM-affiliated enrollment site. * Patients who have elected to undergo OCS with the WCM-affiliated obstetrics provider * Patients with prior OCS but planned to repeat OCS are eligible * Patients can speak and read in English or Spanish Exclusion Criteria: * Patients who have previously completed a multigene hereditary cancer syndrome panel * Patients who have a hematologic cancer or hematologic pre-cancer * Patients who have a history of an autologous bone marrow transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary cancer syndromes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hereditary neoplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary cancer syndromes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • NewYork-Presbyterian Weill Cornell Medicine

    NOT_YET_RECRUITING

    Brooklyn, New York, 11215, United States

  • NewYork-Presbyterian Weill Cornell Medicine Queens

    RECRUITING

    Queens, New York, 11355, United States

  • Reproductive Medicine

    RECRUITING

    Brooklyn, New York, 11201, United States

  • Reproductive Medicine

    RECRUITING

    New York, New York, 10021, United States

  • Weill Cornell Medicine

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.